Medication for treatment of psoriasis

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular for treatment of psoriasis. Medication for treatment of psoriasis, which contains solution of phospholipids in 70% ethyl alcohol and water solution of sodium deoxyribonucleate, components being taken in specified ratio.

EFFECT: medication is efficient for treatment of psoriasis.

4 ex

 

The invention relates to medicine and can be used for the effective treatment of psoriasis.

In the prior art it is known external remedy for skin regeneration based on liposomal preparation containing a solution of lipids in an organic solvent, and a bioactive active substance (EN 2036637, AK 7/00, 1995; EN 2303977, A61K 9/127, 2007). This drug, which may have soft dosage form, is a cosmetic product is not suitable for the treatment of psoriasis.

It is also known medication for the treatment of psoriasis in the form of a spray containing a pharmaceutically acceptable carrier a therapeutically effective amount of the active substance (clobetasol propionate in dissolved form; calcitriol in dissolved form), alcohol phase at least one volatile silicone and a non-volatile oily phase (RU 2007101542 AND AC 31/593, 2008). However, the use of such drugs in the form of a spray for the treatment of psoriasis may be insufficient.

The invention is directed to the creation of medicines on the basis of liposomal drug that provides effective treatment of psoriasis.

The solution of this problem is provided by the fact that drug for the treatment of psoriasis based on liposomal preparation according to the invention contains a solution of lipids is an organic solvent and an aqueous solution of biologically active substances, the biologically active substance used deoxyribonuclease sodium in liposomes in the following ratio, wt.%:

deoxyribonuclease sodium0,01÷0,04
phospholipids1,0÷2,0
the organic solvent is ethyl alcohol7÷14
waterrest

In addition, the solution of the problem provided that the medicinal product for the treatment of psoriasis based on liposomal preparation according to the invention is made in soft dosage form ointment and contains a binder in an organic solvent and liposomal preparation comprising an aqueous solution of biologically active substances, as a biologically active substance using deoxyribonuclease sodium in liposomes, and the binder contains a polymer Carbopol" and hydroxide sodium in the following ratio, wt.%:

"Carbopol"0,8÷1,2
sodium hydroxide0,025
deoxyribonuclease sodium0,0015÷0,0065
phospholipids0,15÷0,32
the organic solvent is ethyl alcohol1,15÷2,30
waterrest

Therapeutic efficiency in use of the drug for the treatment of psoriasis due to the fact that deoxyribonuclease sodium is an immunomodulator with a pronounced anti-inflammatory action. In addition, the effect obtained in accordance with the invention of the drug in the form of a homogeneous suspension of liposomal vesicles, which can be used in the dosage form in the form of ointments or sprays, also due to the fact that enclosed in a lipid membrane, consisting mainly of neutral and negatively charged phospholipid, biologically active ingredient - deoxyribonuclease of sodium in the external treatment of the affected areas of the skin to actively penetrate deep into the skin, effectively showing their immunocorrective and anti-inflammatory properties.

The claimed preparation prepare as follows. The lipid to mponent - the phospholipid extract (for example, "Lipovac") dissolved in a water-soluble organic solvent (e.g. ethanol 70% ethanol) to obtain a 10% concentration of phospholipids and mixed in a ratio of 1:1 with 0.1% aqueous solution of the active substance - deoxyribonuclease sodium, prepared, for example, by dissolving 0.02 wt. hours of deoxyribonuclease sodium 20 wt. including distilled water), pour the mixture into a container and add the remaining amount of distilled water to obtain aqueous suspensions of liposomes with the stated ratio of the components. Thus prepared medicinal products for the treatment of psoriasis on the basis of deoxyribonuclease sodium in the form of liposomal drug caused mainly in the form of aerosol flow through the atomization of the sealed containers under pressure, for example, a neutral gas (air or propellant)on the affected areas of skin.

In addition, the claimed medicinal product may be prepared in the form of ointments as follows:

For preparation of ointment 500 g ointment polymer "Carbopol" injected into 40 liters of distilled water and incubated for 3 hours to fully swell the polymer is stirred until a homogeneous homogeneous substance, which then with continuous stirring prikaspian who eat add 80 ml of 4M sodium hydroxide solution. In the resulting gel is injected 20% by weight (8 kg) liposomal component, prepared according to the above technology and mix until you get a smooth cream.

Claimed, the drug can be used both independently and in complex therapy for the treatment of psoriasis.

Example 1

Patient G., 33 years. In the dermatology Department of the clinical hospital sent with the diagnosis of Common psoriasis ". As the external treatment in stationary phase received liposomal preparation containing 0.01 wt.% desoxyribonuclease sodium. On the 14th day of the disappeared itching, degenerate new papules. By the 15th day decay plaques on the upper limbs increased the number of hyperpigmented areas. The 17 day plaques throughout the surface of the affected fully "broken up" into separate and observed multiple hyperpigmented rash. To 18 days, the rash completely acquired spotty nature - came regressing stage psoriatic process. By the time of discharge from hospital (21 days from start of treatment), the patient was observed single hyperpigmented spots in the upper limbs and trunk and multiple areas of hyperpigmentation and cyanothece-red spots in the lower extremities.

Example 2

Patient M., 21 years. In the dermatological Department of clincheck the th hospital were treated with the diagnosis of Limited Palmar-plantar psoriasis. As the external treatment in stationary phase received liposomal preparation containing 0.025 wt.% desoxyribonuclease sodium. On the 11th day disappeared itching, degenerate new papules. To a 14-day plaques throughout the surface of the affected fully "broken up" into separate and observed multiple hyperpigmented rash. By the time of discharge from hospital (20 days from start of treatment), the patient was observed single hyperpigmented spots in the field of palms and multiple areas of hyperpigmentation and cyanothece-red spots in the area of the soles.

Example 3

Patient S., aged 45, was treated in the dermatology Department with a diagnosis of "Widespread pustular psoriasis". As the external treatment in stationary phase received liposomal preparation containing 0,04 wt.% desoxyribonuclease sodium. To 16 days from the start of treatment, all plaques were flat, cleared purulent discharge the color from bright red has become a pale pink. Complete resolution of the rash came to 21 days from the start of treatment.

Example 4

Patient E., 36 years old, came with complaints about the presence of itchy pink scaly plaques in the area of the scalp, trunk, upper and lower extremities. Was previously diagnosed with "Common psoriasis". As external therapy in stationen the Dalet handled the areas of affected skin ointment, containing liposomal preparation of 0.003 wt.% desoxyribonuclease sodium. To 11 days from the start of treatment, 40% papular absentem bought a flat shape; there was a decrease in the total number of papular-plaque elements. By the 15th day from the start of treatment all plaques were flat, the color of bright red has become a pale pink. Complete resolution of the rash came to 19 days of treatment.

Drug for the treatment of psoriasis on the basis of deoxyribonuclease sodium, characterized in that it contains the solution of phospholipids in 70%ethyl alcohol and aqueous solution of deoxyribonuclease sodium, and the components are taken in the following ratio, wt.%:

deoxyribonuclease sodium0,01-0,04
phospholipids1,0-2,0
70%ethanol7,0-14,0
waterrest



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a compound of formula I ; or to its pharmaceutically acceptable salts where n represents 0, 1 or 2; Y1 represents a bond or a group C(O); Y2, represents a bond, the groups C(O) or S(O)2; R1 represents hydrogen, halogen, cyano, C1-2alkyl; R2 represents hydrogen, halogen, cyano, C1-4alkyl, C1-3alkoxy, halogen-substituted-C1-3alkyl, halogen-substituted-C1-3alkoxyl, C6aryl-C0alkyl, tetrazolyl, C3-6cycloalkyl-C0alkyl, C6-7heterocycloalkyl-C0-4alkyl where 1 or 2 carbon atoms in the ring are substituted by the groups selected from -O-, -NH-, -S(O) and -SO2-; and phenoxy groups; where said aryl and heterocycloalkyl groups R2 can be substituted by 1 or 2 radicals independently selected from C1-6alkyl; R3 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group and a group -NR6aR6b where R6a and R6b are independently selected from hydrogen and C1-4alkyl; R4 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group; R5 represents hydrogen or C1-3alkyl group; L represents a bivalent radical selected from ; ; ; ; ; ; ; ; ; ; ; ; and ; where asterisks the junctions of Y2 and R2; where any bivalent radical L can be substituted by 1 or 2 radicals independently selected from halogen, hydroxy, cyano, C1-4alkyl, C1-4alkyl carbonylamino, C1-4alkoxy, C1-4alkoxycarbonyl, halogen-substituted - C1-4alkyl, C1-3alkylsulfonyl, C1-3alkylsulfonyl-amino, cyano-substituted - C1-4alkyl and halogen-substituted -C1-4alkoxy radicals. Also, the invention refers to a method of Hedgehog path inhibition in a cell and to a method of undesired cell proliferation inhibition which involves the interaction of the compound of formula I and the cell.

EFFECT: new substituted imidazole derivatives which can be effective in treatment of some types of cancer are prepared.

13 cl, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I, which are HSP90 (heat-shock proteins) inhibitors and can be used to prepare a medicinal agent for treating tumorous diseases affected by HSP90 inhibition. In formula I R1 denotes Hal, H, OA or A, R2, R3 each independently denotes -O-(X)s-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSOr(X)s-Q, NHCOA, Hal, Het or H, where, if R2=H, then R3≠H, or if R3=H, then R2≠H, R4 denotes H, R5 denotes H, Hal, A, OA, (CH2)nCOOH, (CH2)nCOOA, O(CH2)oCONH2, NHCOOA, NHCO(CH2)nNH2, NHCONHA or O(CH2)oHet1, A denotes a straight or branched alkyl containing 1-10 carbon atoms, in which 1-5 hydrogen atoms may be substituted with F, Cl and/or Br, X denotes a straight or branched C1-C10 alkylene which is unsubstituted or substituted once, twice or thrice by A, O A, OH, Hal, CN, COOH, COOA, CONH2, NH2, NHCOA, NHCOOA, Q denotes H, Ar or Het, Ar denotes phenyl which is unsubstituted or substituted once, twice or thrice with A, OA, OH, NO2, Hal, CN, (CH2)nCOOH, (CH2)nCOOA and/or tetrazole, Het denotes a cyclic saturated or aromatic 5-6-member heterocycle containing 1-2 N and/or O atoms, optionally condensed with a benzene ring which may be substituted once, twice or thrice with A, OA, OH and/or =O (carbonyl oxygen), Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N and/or O atoms, which may be mono- or disubstituted with A, OA, OH, Hal and/or =O (carbonyl oxygen), Hal denotes F, Cl, Br or I, n equals , 1, 2, 3 or 4, o equals 1, 2 or 3, s equals 0, 1 or 2.

EFFECT: high efficiency of using said derivatives.

4 cl, 4 dwg, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to certain N-alkylcarbonylaminoacid esters of formula where R1 independently represents hydrogen or methyl; R2 independently represents alkyl C1-C2 and R3 independently represents alkyl C1-C4, offered in the present invention, as well as to compositions and therapies with using the declared compounds.

EFFECT: preparing new compounds which effect on sensory processes.

27 cl, 7 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry, and deals with medication for local application for treating dermatitis, selected from atopic dermatitis, contact dermatitis, or seborrheic dermatitis, as well as for treatment of psoriases or eczema.

EFFECT: medication has high efficiency in treatment of atopic dermatitis, psoriases or eczema.

3 cl, 3 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to dermatology. A method involves administration of a sorption corrective agent presented by Lamifaren gel. Gel is taken by 50-150 g 3 times a day 30 minutes before meals. Low-mineralised nitrogenous siliceous baths of radon concentration 4-6 nCu/l at temperature 37-38°C are taken. Then wet skin of the involved regions is coated with Lamifaren gel 3-6 times a day to complete drying of gel. The therapeutic course is 10-14 baths. After termination of a course of baths, Lamifaren gel is consumed internally and applied externally to complete relief of a skin process.

EFFECT: method reduces a number of allergic reactions due to decreased drug administration and prolongs remission.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to dermatology. The method involves total mud applications of salt-saturated sulphidic silt mud at temperature 40-42°C, duration of a procedure 20 minutes. The mud applications are alternated with taking baths every second day. The baths are prepared of iodide-bromine sodium chloride mineral water "Tinakskaya", at temperature 36-37°C, for 10-15 minutes. Total duration of treatment is 20 days.

EFFECT: method provides higher sanatorium-and-spa effectiveness in the patients.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention is referred to medicine, dermatology, and can be used for treating patients with psoriasis. That is ensured by a complex pathogenetic therapy followed by a photodynamic therapy. As a photosensitiser, the preparation photosense in ointment form is used. Photosense is applied on psoriatic skin rashes at concentration of an active substance 0.001-0.01 g/cm2. Duration of an application is 1-12 hours. It is followed with local light radiation of pathological nidi at wave length 675 nm and power density 40 mWt/cm2.

EFFECT: method allows to provide effective, low-toxic psoriasis treatment with prolonged remission, ensured complete clinical remission with minimum by-effects.

3 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel pyrimidine derivatives of general formula I, as well as to their diastereoisomers, enentiomers and/or pharmaceutically acceptable salts, which possess inhibiting action with respect to cyclin-dependent kinases and/or tyrosinekinases of VEGF receptor. In compound of general formula (I) Q stands for group where D, E, G, L, M and T in each case represent carbon, R1 represents hydrogen, halogen or CF3, R2 represents C1-C10-alkyl, which can optionally be disrupted with one group-C(O), C2-C10-alkinyl, C3-C10-cycloalkyl or phenyl, which is optionally substituted in one or more places in similar or different way by hydroxyl, halogen, C1-C6-alkoxy, C1-C6-alkyl, C3-C10-cycloalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkoxy-C1-C6-alkyl or -COR8, X represents oxygen, sulphur or group -NH-, R3 represents hydroxy, halogen, CF3 or C1-C6-alkoxy, m represents 0-4, R4 represents hydrogen or group -COR8, NO2 or -SO2R7, or represents C1-C10-alkyl or C3-C10-cycloalkyl, R5 represents C1-C10-alkyl, which can be optionally substituted in one or more places, in similar or different way, by hydroxyl or C3-C10-cycloalkyl, or C3-C10-cycloalkyl, R7 represents C1-C10-alkyl, which is optionally substituted by group trimethylsilanyl (TMS), R8 represents C1-C6-alkyl, C1-C6-alkoxy. Invention also relates to intermediate compounds.

EFFECT: compounds can be applied for obtaining medication intended for treatment of cancer, selected from Kaposhi's sarcoma, Khodgkin's disease, leukemia or solid tumour, such as carcinoma of mammalian gland, kung, large intestine or prostate gland, autoimmune disease, such as psoriasis, and/or proliferative diseases, such as hemangioma or angiofibroma.

21 cl, 3 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to new compounds of formula (1) or its pharmaceutically acceptable salts, with properties of antagonist CXCR2 of human neutrophils receptor. In formula (1) R1 represents a group selected from C1-8alkyl; where this group is possibly substituted with 1 substituent, independently selected from phenyl or 5-6-unit heteroaryl, containing 1-2 heteroatoms selected from N, S; where phenyl and heteroaryl are possibly substituted by 1, 2 or 3 substitutors, independently selected from halogeno, cyano, -OR4, -COOR7, -SO2R10, C1-6alkyl; X represents -CH2-, oxygen, sulfur; R2 represents C3-7carbocyclil, possibly substituted with 1, 2 or 3 substituents, independently selected from -OR4; or R2 represents 5-unit ring, containing 2 heteroatoms, selected from O, -NR8, and where this ring is possibly substituted with 1 substituent, independently selected from C1-3alkyl; or R2 represents group, selected from C1-8alkyla, where this group is substituted with 1, 2 or 3 substituents, independently selected from hydroxy, amino, C1-6alkoxy, C1-6alkylamino, di(C1-6alkyl)amino, N-C1-6alkylcarbamoyl, N,N-di(C1-6alkyl)carbamoyl, carboxy, -NR8COR9 and -CONR5R6; R3 represents group -NR5R6, or R3 represents phenyl, possibly condensed with 6-unit heterocyclil, containing nitrogen, naphthyl, 4-8-unit monocyclic heterocyclil, containing 1-3 heteroatoms, selected from N, O, S, possibly condensed with benzole ring or 3-unit nitrogen-containing ring, where heteroring may be non-saturated, partially or fully saturated, and one or more than one circular atom of carbon may form carbonyl group, and where each phenyl or heterocyclil group is possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, cyano, phenyl, 5-6-unit heteroaryl, containing 1-2 atoms of nitrogen, -OR4, -NR5R6, -CONR5R6, -COR7, -COR20, -COOR7, -NR8COR9, -SO2R10, -SO2NR5R6 or C1-6alkyl [possibly additionally substituted with 1, 2 or 3 substituents, independently selected from halogeno, cyano, -OR20, -COOR20, -NR18R19, -CONR18R19, phenyl or 5-6-unit of monocyclic heteroaryl, containing 1-2 heteroatoms O, N, S, or 10-unit bicyclic heteroaryl, containing 1 heteroatom O, where heteroring may be partially or fully saturated, and where each phenyl or heteroaryl is group possibly substituted with 1 or 2 substituents, independently selected from halogeno, cyano, nitro, -OR20, -NR5R6, -COOR7, -NR8COR9, 6-unit heterocyclil, containing two heteroatoms, selected from O and N, 5-unit heteroaryl, containing 3 heteroatoms N, C1-6alkyl (possibly additionally substituted with 1 substituent, independently selected from halogeno, cyano, nitro, -OR20, -COOR20; or R3 represents group, selected from C3-7carbocyclil, C1-8alkyl, where this group is possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR4, -NR5R6; R4 represents hydrogen; R5 and R6 independently represent hydrogen or group, selected from C1-6alkyl and monocyclic 6-unit saturated heterocyclil containing 1 heteroatom N; where C1-6alkyl is possibly substituted with 1 substituent, independently selected from -NR15R16; or R5 and R6 together with atom of nitrogen, to which they are linked, form 4-7-unit saturated heterocyclic circukar system, possibly containing additional heteroatom, selected from oxygen, -SO(n)- (where n equals 0, 1 or 2) and atoms of nitrogen; R10 represents hydrogen or group, selected from C1-6alkyl; and each of R7, R8, R9, R15, R16, R17 independently represents hydrogen, C1-6alkyl; R18, R19 and R20 represent hydrogen or group, selected from C1-6alkyl, where this group is possibly substituted with 1 substituent, independently selected from -NR8R9, -CONR8R9.

EFFECT: production of new compounds, which may find application in production of medicinal agent for use in treatment of diseases and disorders mediated with chemokines, such as asthma, allergic rhinitis, chronic obstructive pulmonary disease, inflammatory intestine disease, irritable colon syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis or psoriasis, and also for treatment of cancer.

12 cl, 155 ex

FIELD: chemistry.

SUBSTANCE: novel compounds have general formula (1), or salts thereof:

, where R10 is cyclohexyl optionally substituted with a substitute selected from group A1, or cyclohexenyl optionally substituted with a substitute selected from group A1, R30, R31 and R32 denote hydrogen, R40 denotes C1-10alkyl optionally substituted with a substitute selected from group D1, n equals 0 or 1, X1 denotes nitrogen, and R20, R21, R22 and R23 independently denote hydrogen, except when R20, R21, R22 and R23 all denote hydrogen, C1-6 alkylthio optionally substituted with a substitute selected from group F1, C2-6 alkoxycarbonyl, C1-6 alkyl substituted with a substitute selected from group W1, C1-6 alkyl substituted with a substitute selected from group K1, C1-6 alkoxy substituted with a substitute selected from group W1, a 5-6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or S atoms, substituted with a substitute selected from W1, a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or S atoms, substituted with a substitute selected from group V1, pyridyl substituted with a substitute selected from group W1, phenyl,optionally substituted with a substitute selected from group W1, C2-7 alkenyl, optionally substituted with a substitute selected from group W1, C2-7 alkynyl optionally substituted with a substitute selected from group W1, a 3-6-member cycloalkyl optionally substituted with a substitute selected from group W1, a 5-6-member cyclalkenyl optionally substituted with a substitute selected from group W1, NR1XR2X, -CO-R1X, -CO-NR1XR2X, -NR1X-CO-R2X, -SO2-R3X or -O-SO2-R3X,where R1X is hydrogen or a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N and O atoms, R2X is a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or O atoms, and R3X is C1-6 alkyl optionally substituted with a substitute selected from group F1; or R21 and R22 together form a ring selected from group Z1, where group A1 consists of C1-6 alkyl, group D1 consists of cyclopropyl and tetrahydropyranyl, group F1 consists of a halogen, group W consists of hydroxyl, C2-7 alkoxyalkyl, phenoxy, C2-7 alkoxycarbonyl, -NR6XR7X and -CO-NR6XR7X, where R6X and R7X independently denote hydrogen or C1-6 alkyl, group V1 consists of oxo (=O) and ethylenedioxy(-O-CH2CH2-O-), where ethylenedioxy is allowable only if a compound of two rings with one common atom forms together with a substituted 6-member heterocyclic group, group K1 consists of a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or O atoms, group U1 consists of carboxyl, C1-6 alkoxy, phenyl and CO-NR8XR9X, where R8X and R9X denote hydrogen, and group Z1 consists of

, where R1Z denotes C1-6 alkyl or benzyl. The invention also pertains to a medicinal agent, a cell adhesion or cell infiltration inhibitor, as well as to therapeutic or prophylactic agents.

EFFECT: obtaining novel biologically active compounds having cell adhesion or cell infiltration inhibiting activity.

20 cl, 147 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: in claimed invention it suggested are liposome compositions, which contain substituted ammonia and/or polyanion and, optionally, desirable therapeutic agent or expressing contrast substance.

EFFECT: invention provides efficient method of obtaining liposome compositions.

141 cl, 40 tbl, 74 ex, 47 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of biotechnology, namely, to obtaining liposomal dispersions for cosmetic and medicinal purposes. Claimed dispersions can be applied as delivery systems into living organisms of biologically active substances. Result is reached by introduction into composition of initial lipid mixture of alkanes C 16-C38 both in individual form, and in form of compound mixtures, mainly in quantities 5-20% mole, if necessary quantity of alkanes is increased up to complete saturation of bilayer with introduced alkanes.

EFFECT: insuring possibility of regulating (controlled reduction) permeability of liposome bilayer, which makes it possible to create systems of delivery of biologically active substances with preliminarily defined parameters of release.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and deals with nanoliposome which includes liposomal membrane, contains ethgerificated lecitin and one or more physiologically active ingredients, incorporated in the internal space of liposomal membrane, method of obtaining such, as well as composition for prevention or treatment of skin diseases, containing nanoliposome.

EFFECT: invention ensures long-term stability and homogenecity of nanoliposomes.

15 cl, 22 ex, 4 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, and concerns a pharmaceutical composition for treating rheumatic and inflammatory diseases representing phospholipid nanoparticles sized 10-30 nm, including herbal phosphatidylcholine, maltose and indometacin in the following proportions, wt %: phosphatidylcholine 20-43, maltose 55-78, indometacin 2-8.

EFFECT: pharmaceutical composition exhibits higher antirheumatic and anti-inflammatory activity in oral and intravenous introduction.

1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to methods for producing wound healing drugs for external application. Producing a liposomal agent exhibiting wound healing action requires phospholipid extraction from Baikal seal liver; prepared mixed phospholipids and Baikal seal fat are dissolved in an organic solvent in the ratio 4:6 with the antioxidant α-tocopherol added. A thin layer of lipids is dried in a rotary evaporator; a buffer solution is added; the mixture is agitated to prepared a homogeneous suspension. It is followed with ultrasound preparation of the lipid mixture with water cooling. The liposomal suspension mixed in the ratio 1:1 with pre-melted mixed polyethylene glycols 1000 and 6000 Da taken in the ratio 9:1. Further, the produced mixture is homogenised to a homogeneous mass.

EFFECT: use of the method allows producing the liposomal agent for external application exhibiting wound healing action.

3 tbl, 3 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmacology and deals with pharmaceutical composition of arbidol in form of phospholipid nanoparticles with size 8-25 nm, which includes phosphatidylcholine, maltose and arbidol with the following component ratio, wt %: phosphatidylcholine- 20-43%, maltose- 55-78%, arbidol- 2-8%.

EFFECT: composition possesses low toxicity, stability in long-term storage and high bioavailability.

4 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to pharmaceutical composition for treatment of oncologic diseases in form of phospholipid nanoparticles with size 10-30 nm, which includes phosphatidelcholin, maltose and doxorubicine with the following ratio of components, wt. %: phosphatidelcholin 20-43, maltose 55-78, doxorubicine 2-8. Composition is accumulates in tumour tissue more actively and slows down tumour growth in mice with carcinoma LLC more efficiently in comparison with free doxorubicine.

EFFECT: composition represents freeze-dries powder, stable in long storage, which dissolving in water gives nanophpospholipid particles with included doxorubicine.

3 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: invention refers to an immunoliposomal form of a photosensitiser form on the basis of tetra-3-phenylthiophthalocianine aluminium hydroxyl which is used in photodynamic therapy of malignant tumours. The immunoliposomal form contains said photosensitiser (0.011 g), egg phosphatidylcholine (2.2 g), cholesterol (0.264 g), mPEG2000-DSPE [methoxy(polyethylene glycol-2000)] 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N (0.0528 g), (pNP-PEG3400-DOPE) 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-N-[n-nitrophenylcarbonyl (polyethylene glycol-3400)] (0.0176 g), triple-substituted sodium citrate (0.53 g) and anti-CD5 MCA (ICO-80) (anti-CD5 monoclonal antibodies) (0.00237 g).

EFFECT: high phototoxic effect.

3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: method for producing immobilised bilayer vesicles is ensured by processing a carrier containing graft polymer chains, with a bilayer vesicle suspension in water or a water-salt solution. In implementing said method, the carrier is presented with modified solid surfaces or modified disperse particles. The given carriers contain at least one cationic or anionic graft polymer of polymer density not less than 200 polymer chains per one square micron of a carrier surface. The bilayer vesicles are anionic or cationic vesicles consisting of at least one amphiphile surface-active substance and carrying a surface charge opposite in sign to a charge of the polymer-modified carrier surface.

EFFECT: simplified method for producing immobilised bilayer vesicles.

2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel surfactants of formula III and their use in obtaining nanoparticles which serve as vectors for biologically active ingredients. , and , where R3 is selected from group IV or V; Y is a sulphur atom or -NH-CO-(CH2)n-X-; X is a sulphur atom or -CH2-; n and y are integers from 0 to 10; R is a hydrocarbon, fluorinated hydrocarbon or thioalkyl; W is -NH- or CH2-; p is an integer from 1 to 50; m is an integer from 0 to 9; and if X = CH2, 0 < m+n < 6; x is an integer from 0 to 30; R1 is selected from the following radicals: where R' is H or polyhydroxylated hydrocarbon; R2 is an identification group which has affinity to a biological target; Z is a spacer group.

EFFECT: design of novel surfactants and nanoparticles based on the said surfactants.

22 cl, 9 ex, 2 tbl, 8 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to gastroenterology, and can be used for treatment of intestinal diseases. For this purpose applied is intrarectal introduction of compounds which cause RNA interference. In addition, claimed are RNKi compounds with specified nucleotide sequence, causing RNA-interference and intended for intrarectal introduction, whose target is interleukin-12 gene. Claimed compounds can also be used for treatment of intestinal diseases.

EFFECT: inventions ensure efficient disease treatment due to efficient reaching and impact in action targets.

43 cl, 1 tbl, 5 ex, 9 dwg

Up!